Duke University Med Ctr Printed as of 12/4/2025

# **Disclosures**

# Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Artivion	Research/Research Grants ‡ PROACT-Xa	Significant (>= \$5,000)	Valvular Heart Disease
AtriCure	Data Safety Monitoring Board	Modest (< \$5,000)	Cardiothoracic Surgery
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ PACIFIC-AMI, OCEANIC-AF	Significant (>= \$5,000)	Acute Coronary Syndromes Arrhythmias and Clinical EP
Bristol Myers Squibb	Consultant Fees/Honoraria	Significant (>= \$5,000)	Arrhythmias and Clinical EP General Cardiology
Bristol Myers Squibb	Research/Research Grants ‡ AUGUSTUS	Significant (>= \$5,000)	Arrhythmias and Clinical EP General Cardiology
CSL Behring	Research/Research Grants ‡ AEGIS I, AEGIS II	Significant (>= \$5,000)	Acute Coronary Syndromes
Curis	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Eli Lilly and Company	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
Ferring Pharmaceuticals	Research/Research Grants  ‡ PRONOUNCE	Significant (>= \$5,000)	General Cardiology
Humacyte	Consultant Fees/Honoraria	Modest (< \$5,000)	Cardiothoracic Surgery
Novostia	Consultant Fees/Honoraria	Modest (< \$5,000)	Valvular Heart Disease
Theravance	Data Safety Monitoring Board	Modest (< \$5,000)	Vascular Medicine
Veralox	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (2)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
National Institutes of Health	Research/Research Grants ‡ PACeS as part of the CTSN	None (\$0)	Cardiothoracic Surgery
US Food and Drug Administration	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

# Clinical Trial Enroller (0)

No disclosures on record

# Institutional Financial Decision-Making Role (0)

No disclosures on record

# Expert Witness Testimony (0)

† Commercial Funding Source | ‡ Trial Name

# Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/27/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/27/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/27/2025

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.